The mission of the Cancer Risk and Disparities Program is to support research that will lead to a reduction of cancer risk and disparities across society. To achieve this goal, the Program has the following four specific aims: 1. Understand the individual, psychosocial, organizational and community-level factors that determine differences in cancer risk across the life course and population groups. 2. Develop, test and evaluate interventions to reduce cancer risk across the life course and population groups. 3. Advance the science of communication and knowledge translation to promote dissemination of evidence-based interventions to reduce cancer risk. 4. Examine causes of disparities in cancer risk and incidence and Identify interventions to redress these disparities. The Program was initially funded in 2000 when the Dana-Farber/Harvard Cancer Center was established as a consortium Center, and received a merit score of """"""""excellent to outstanding"""""""" at the time of the last renewal in 2005. The Program Is led by L. Frazier(DFCI). There are two Co-Leaders: K. Viswanath (DFCI) and D. Williams(HSPH). During the current project period, the goals of the Program were substantially revised to include new research foci including: 1) the individual and societal factors that predispose to cancer risk, 2) the science of dissemination and 3) an explicit focus on cancer disparities, all of which represent expanded and vibrant strengths within the Program. The expertise of the 49 members spans epidemiology, molecular epidemiology, behavioral science, communication science, intervention science, health policy and dissemination. In 2009, the Program received $19.7 million in cancer-relevant funding (total costs), which included over $11.9 million in NCI funding and $6.5 million in other federal, peer-reviewed funding. Attesting to the productivity and interactivity of the Program are the 903 publications authored by members of the Program during the project period (2006 to 2010), of which 15.5% were Intra-programmatic ,18% were inter-programmatic and 16% were inter-institutional collaborations.

Public Health Relevance

The Cancer Risk and Disparities Program seeks to identify the causes of increased risk of cancer, to design interventions to address these causes and to disseminate this knowledge effecfively into the community by advancing the methodologies of communication science and knowledge translafion. The Program is committed to reducing the incidence of cancer and its unequal distribution in the US population through its research and involvement in health and social policy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,766
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574
Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641
Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351

Showing the most recent 10 out of 411 publications